Abstract Number: 1320 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Background/Purpose: Anemia of chronic disease, a common extra-articular manifestation of rheumatoid arthritis (RA), which has a substantial impact on patient function, is driven in part…Abstract Number: 1321 • 2012 ACR/ARHP Annual Meeting
C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of B Cell Activating Factor in Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their clinical response to treatment. Despite considerable research, no…Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting
Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis
Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…Abstract Number: 1323 • 2012 ACR/ARHP Annual Meeting
Effects of Dose Escalation of Tocilizumab in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs: Sub-Analysis of a 24-Week Study in a United States Population
Background/Purpose: In the US, the recommended starting dose of Tocilizumab (TCZ) is 4 mg/kg (q4w) with an increase to 8 mg/kg (q4w) based on clinical…Abstract Number: 1324 • 2012 ACR/ARHP Annual Meeting
Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks As Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy: Week 104 Results of Clinical, Radiographic and Safety Assessments
Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks as Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy:…Abstract Number: 1325 • 2012 ACR/ARHP Annual Meeting
Prevention of Joint Destruction in Patients with High Disease Activity or High C-Reactive Protein
Prevention of Joint Destruction in Patients with High Disease Activity or High C-reactive proteinBackground/Purpose: In Japan, 2 doses (50mg and 100mg) of golimumab (GLM) were…Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting
Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons
Background/Purpose: The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…Abstract Number: 1327 • 2012 ACR/ARHP Annual Meeting
Comparison of Four Different Intensive Treatment Strategies in Patients with Early Rheumatoid Arthritis in Korea
Background/Purpose: The previous studies reported that intensive treatment-strategies, including biological agents and glucocorticoids, can improve the severity of early rheumatoid arthritis. However, there was no…Abstract Number: 1328 • 2012 ACR/ARHP Annual Meeting
The Higher and Faster Increasing Schedule of Methotrexate May Not Be the Best: The Accumulation of Intracellular Longer Chain Methotrexate Polyglutamates Was Facilitated by the Extra-Low-Dose Methotrexate Treatment
Background/Purpose: Although data are conflicting with regard to the clinical utility of MTX polyglutamates (PGs) measurements as a predictor of the efficacy or toxicity in…Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting
Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…Abstract Number: 1330 • 2012 ACR/ARHP Annual Meeting
High Body Mass Index Is Associated with Decreased Response to Initial Combination Therapy in Recent Onset RA Patients
High BMI is associated with decreased response to initial combination therapy in recent onset RA patients Background/Purpose: A diminished response to combination treatment with a fixed…Abstract Number: 1331 • 2012 ACR/ARHP Annual Meeting
Once Daily High Dose Regimens of GLPG0634 in Healthy Volunteers Are Safe and Provide Continuous Inhibition of JAK1 but Not JAK2
Background/Purpose: GLPG0634 is an orally-available, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 0.6 μM and a 30-fold selectivity over JAK2 in…Abstract Number: 1332 • 2012 ACR/ARHP Annual Meeting
The Incidence of Exacerbation of Pre-Existing Interstitial Lung Disease (ILD) Is Higher in TNF Blockers Than in Non-TNF Blockers in RA
Background/Purpose: Exacerbation of interstitial lung disease (ILD) is a problem when biologics are administrated in patients with RA, and not a few fatal cases have…Abstract Number: 1333 • 2012 ACR/ARHP Annual Meeting
The Predictive Value of CD64 Counts for Infectious Disease in Patients Treated with Tocilizumab On the Infectious Disease Risk Management Cohort (ACT4U-study)
Background/Purpose: An administration of tocilizumab (TCZ) rapidly suppresses inflammatory markers such as CRP and ESR, which makes the diagnosis of infection difficult. There is a…Abstract Number: 1334 • 2012 ACR/ARHP Annual Meeting
Intra-Articular Etanercept Treatment in Inflammatory Arthritis: A Randomized Double-Blind Placebo-Controlled Trial
Background/Purpose: The use of intra-articular (IA) corticosteroid injections has been widely accepted as a therapy to control local inflammation. Studies on the use of IA…